Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...
The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback